Genedrive® System

Empowering clinicians with rapid results to improve patient outcomes

The Genedrive® System is a rapid, genetic testing platform that provides automated results in clinically relevant timeframes. Developed in partnership with healthcare professionals, it enables fast, informed clinical decisions right at the bedside without the need for specialised equipment or training.

Traditional laboratory workflows can take days or even weeks. With the Genedrive® System, rapid results are available in clinically relevant timeframes, empowering clinicians to make timely decisions in critical care pathways such as stroke, cardiology and sepsis where even minor delays can dramatically affect patient outcomes.

Genedrive empowers non-laboratory professionals by providing easy-to-use, rapid genetic testing without the need for specialised equipment or complex infrastructure. This removes traditional barriers to testing and accelerates treatment, wherever care is needed.

With on the spot results, there’s no need for follow-up calls, delayed prescriptions, or unnecessary appointments. The Genedrive System reduces backlogs and readmissions while improving patient engagement by enabling clinicians to explain results there and then, enhancing both efficiency and patient experience.

Patients: Patients can expect to benefit from personalised treatments that lead to improved outcomes. Receiving treatment decisions quickly reduces the likelihood of re-admissions or prescription changes, resulting in a simpler, more effective care plan.

Healthcare Providers: The Genedrive® System empowers clinicians with rapid, easy-to-use testing with clear, actionable results. It streamlines workflows, reduces delays, and helps lower re-admission rates, freeing up time and resources for better patient care.

Why choose the Genedrive® System
icon-0
Time critical settings
Provides rapid, automated results in clinically relevant timeframes, enabling timely treatment decisions in acute care pathways.
icon-1
Compact design
Compact, user-friendly system designed to deliver molecular diagnostics wherever care is required—emergency departments, laboratories, or clinics.
icon-2
Middleware Compatible
View results remotely and automatically upload results into the patient record.
icon-3
CE Marked
Compliant with European regulatory standards.
icon-4
Flexible Testing Platform
Uses nucleic acid amplification and detection technology. Capable of supporting multiple assays for both PCR and LAMP workflows.
icon-5
Intuitive interface
Easy to operate touch screen with barcode scanning ability.
The implementation of the Genedrive MT-RNR1 test across all neonatal sites in Greater Manchester represents a significant advancement in preventing hearing loss in infants and enabling rapid genetic testing at the bedside.
Dr Ajit Mahaveer
Clinical Lead for the Northwest Neonatal Operational Delivery Network (NWNODN)
Manchester’s ground-breaking bedside test for detecting whether an antibiotic could cause deafness in babies in intensive care is another example of how the NHS is harnessing the power of genomic medicine to transform patient care.
Professor Dame Sue Hill
Chief Scientific Officer for England and Senior Responsible Officer for Genomics in the NHS
Having this test available nationally will ensure no baby will go deaf unnecessarily.
Dr John McDermott
Clinical Geneticist at Manchester University NHS Foundation Trust
The development of this new point-of-care diagnostic has the potential to significantly improve care for tens of thousands of patients after a stroke.
Professor William Newman
Professor of Translational Genomic Medicine at the University of Manchester and Lead of the NHSE Network of Excellence in Pharmacogenetics and Medicines Optimisation at Manchester University NHS Foundation Trust
Health Innovation Manchester is pleased to continue to work with genedrive and our academic and health partners to ensure the sustained deployment of this innovative test across the whole of Greater Manchester.
Jonathan Massey
Programme Director for Academia at Health Innovation Manchester
We are delighted to bring the benefit of this novel technology to Stroke patients in our region. Effective clinical management of neurologic stroke relies in part on optimising the efficacy of anti-platelets prescribed, and within a timeframe that is served only by rapid genetic testing technologies such as this. The implementation will help us to formulate a personalised optimal treatment plan for our stroke patients, that we hope will prevent future strokes and save lives.
Professor Radim Licenik
Consultant Stroke Physician, Clinical Lead for Stroke Service and President of the Society of Czech & Slovak Doctors in the UK
Diagnostics when it matters most
Diagnostics when it matters most
Personalised antibiotic treatment

Reducing the risk of antibiotic induced hearing loss in newborns, with rapid results in 26 minutes.

Personalised antiplatelet treatment

Enabling personalised cardiovascular treatment by identifying patient-specific genetic variations.